IMPRINT
Pantarhei Oncology BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheioncology.nl
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by Pantarhei Oncology and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
SOCIAL MEDIA
© 2023
Contribution of Pantarhei Oncology to the 18th World Congress of the IAHR
/in NewsContribution of Pantarhei Oncology to the 18th World Congress of the International Academy of the Human Reproduction (IAHR), April 3-6, 2019 in Dublin by an invited lecture of Herjan Coelingh Bennink.
On Thursday April 4, 2019, a key lecture entitled “Estrogens, Estetrol and Breast Cancer” was given by Herjan Coelingh Bennink, President of Pantarhei Oncology during a scientific session “Oncology, Breast and Gynecological Surgery”. The session was chaired by by Andrea Genazzani. For more information, please read the abstract.
Yvette Zimmerman nieuwe CEO Pantarhei Bioscience: “Wij ontdekken veilige en effectieve nieuwe geneesmiddelen op basis van bestaande menselijke moleculen.”
/in NewsHet Nederlandse biofarmaceutische bedrijf Pantarhei Bioscience heeft met ingang van januari 2019 haar Chief Operating Officer (COO) Yvette Zimmerman benoemd tot Chief Executive Officer (CEO). De oprichter en vorige CEO van Pantarhei, Herjan Coelingh Bennink, is trots op zijn opvolgster: “Yvette is een zeer ervaren ontwikkelaar van nieuwe geneesmiddelen, gemotiveerd door wat echt belangrijk is voor zieke mensen en wat wetenschappelijk vernieuwend is.”
Pantarhei bestaat nu 18 jaar en heeft in die tijd meer dan 220 patenten ingediend. Oorspronkelijk was Pantarhei gericht op het ontwikkelen van nieuwe geneesmiddelen op het gebied van Women’s Health. Sinds de oprichting van het dochterbedrijf Pantarhei Oncology in 2014, is de focus verlegd naar nieuwe hormonale behandelingen van kanker, met name borst- en prostaatkanker.
Lees verder: Persbericht Nieuwe CEO Pantarhei Bioscience
Yvette Zimmerman new CEO Pantarhei Bioscience: “We find safe and effective new treatments using existing human molecules.”
/in NewsPantarhei Bioscience, the Dutch biopharmaceutical company, is pleased to announce the appointment of Yvette Zimmerman as Chief Executive Officer (CEO), with effect from January 2019. The founder of Pantarhei Herjan Coelingh Bennink speaks proudly about his successor: “Yvette is a very experienced drug developer and driven by what is really important for people and scientifically sound.”
During the 18 years of its existence, Pantarhei has filed more than 220 patents. Initially Pantarhei developed new medicines for Women’s Health. Following the foundation of the subsidiary company Pantarhei Oncology in 2014, the focus has been redirected to new treatment concepts for endocrine cancer, especially breast and prostate cancer.
Read more: Press Release New CEO Pantarhei Bioscience